Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

NCT01774578 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer
Progression of Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Recurrent

Interventions

DRUG: Docetaxel
BIOLOGICAL: HyperAcute®-Lung Immunotherapy
DRUG: Gemcitabine
DRUG: Pemetrexed

Sponsor

NewLink Genetics Corporation